Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy-Reference-Cited by-同舟云学术

Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy

Published:2022-12-07 Issue:3 Volume:128 Page:419-420
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bodmer Walter^ORCID

Abstract

SummaryTwo early papers expressing conflicting views on the occurrence of effective immune attack against cancers stimulate an analysis of the gradual development of an understanding of tumour biology. This understanding has led to the development of the strikingly effective check point blocking and CART anti-cancer immunotherapies, and the promise of more widely applicable therapies based on T cell attracting genetically engineered monoclonal antibodies.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-022-02075-z.pdf

Reference14 articles.

1. Hamlin IM. Possible host resistance in carcinoma of the breast: a histological study. Br J Cancer. 1968;22:383–401.

2. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976;33:241–59.

3. Bashford EF, Murray JA, Cramer W. The natural and induced resistance of mice to the growth of cancer. Prod R Soc B. 1907;79:164–86.

4. Rous P. An experimental comparison of transplanted tumor and a transplanted normal tissue capable of growth. J Exp Med. 1910;12:344–66.

5. Little CC, Tyzzer EE. Further experimental studies on the inheritance of susceptibility to a transplantable tumor, carcinoma (j. w. a.) of the japanese waltzing mouse. J Med Res. 1916;33:393–53.